Two important genetic discoveries announced today.
1)
It's happened before with TRIM5 gene
Monkeys have, more than once, evolved a genetic defense to
lentiviruses (which includes HIV). "An intriguing possibility is that the newly formed genes prevented infection by prehistoric viruses related to modern AIDS viruses. If so, this could mean that AIDS-
(
Read more... )
However, in itself, that doesn't really help much to "beat" the epidemic within our lifetimes. All it means is that HIV won't render humans extinct, and that fifty thousand years from now most humans will probably be immune to it.
When it comes to TRIM22, there are quite a few things that can be done with gene therapy in cell cultures, but translating that to living humans is not currently possible in most cases. The gene may lead to a drug candidate that will work, or perhaps (more speculatively) some kind of expression activator that triggers expression of the gene directly in the body. But it's still more likely that any cure will come in the form of a more conventional drug.
Unfortunately, for a virus with so many weak points, it's proven vastly more resilient than any scientist would have guessed 20 years ago. I can't even count the number of critical weaknesses that have been found in this virus, only to find that they are insurmountably difficult to exploit. Someday, though, something's going to nail it.
Reply
Reply
Reply
Reply
Reply
Also, while I'm at it, by far the most interesting HIV work I've seen lately has been this RNAi screen that identified a whole lot more ways HIV can potentially be attacked. It will be quite a while before it translates into therapy, but the wealth of knowledge generated by this experiment is unprecedented.
Reply
Seems like there should be some kind of registry for people willing to participate in a study - and if they match the kind of profile a particular study needs, then they can be contacted.
Reply
At work, we greatly underestimated this problem and found ourselves all dressed up and ready to go - we spent >100M to create the best, most cost-effective genomic screening technology in the world, but ended up without enough human subjects to do the studies we wanted to do with it. And the people who did have patients to work with didn't want to share credit with us by using our services. Nearly killed the company.
Reply
Leave a comment